Evidence map›Paper›PMID 21617154›Full record

ReviewCA: a cancer journal for clinicians

Photodynamic therapy of cancer: an update.

Patrizia Agostinis, Kristian Berg, Keith A Cengel, Thomas H Foster, Albert W Girotti, Sandra O Gollnick, Stephen M Hahn, Michael R Hamblin, Asta Juzeniene, David Kessel and 7 more

2 registry-linked trialsOpen access · diamondAbstract readReview
In one paragraph

Review in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,712 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,712citing papers in PubMed, 3 pooled it
118.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05547516 naunknown statusnot on this map

A Prospective, Multicenter, Randomized Controlled Clinical Study of Blue Laser-5ALA-photodynamic Therapy (PDT) in the Prevention of Postoperative Tumor Recurrence in High-risk Non-muscle-invasive Bladder Cancer

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2022 to 2024Enrolled140ConditionsNon-muscle-invasive Bladder CancerArmsStandard infusion chemotherapy, BL - 5 ala PDT
NCT07488247 phase3recruitingnot on this map

Single-Centre, Open-labeled, Randomized, Phase IIb and Phase III Clinical Studies to Evaluate the Safety, Tolerability, and Efficacy of Chlorin E6 (Gel Formation) as a Photosensitizing Agent for the Management of Diabetic Foot Ulcers With Photodynamic Therapy.

TypeinterventionalSponsorUnited Medical and Dental CollegeRan2026 to 2027Enrolled300ConditionsDiabetic Foot Ulcer (DFU)ArmsChlorin E6 Gel
3 · Its place in the literature

Who cites it

1,712 citing papers in PubMed, 3 syntheses or guidelines pooled it, 5,066 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Design rules for externally triggered drug uncaging under optical and radiolytic regimes.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2026
    Article
  20. Article

1,652 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 5 countries.

Patrizia AgostinisDepartment of Molecular Cell Biology, Cell Death Research and Therapy Laboratory, Catholic University of Leuven, Belgium.
Kristian Berg
Keith A Cengel
Thomas H Foster
Albert W Girotti
Sandra O Gollnick
Stephen M Hahn
Michael R Hamblin
Asta Juzeniene
David Kessel
Mladen Korbelik
Johan Moan
Pawel Mroz
Dominika Nowis
Jacques Piette
Brian C Wilson
Jakub Golab
Oslo University Hospital · NOHarvard University · USMedical University of Warsaw · PLBC Cancer Agency · CACatholic University of America · USMedical College of Wisconsin · USOntario Institute for Cancer Research · CARoswell Park Comprehensive Cancer Center · USRTOG Foundation · USUniversity of Liège · BEUniversity of Pennsylvania · USUniversity of Rochester · USWayne State University · US

Funding

StatisticsP01CA055791 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PANDEY, RAVINDRA K. · 1992 to 2019
$36.0M
TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8M
Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
PHOTOPHYSICS OF PHOTODYNAMIC THERAPYR01CA068409 · NCI · UNIVERSITY OF ROCHESTER · PI FOSTER, THOMAS HARRISON · 1995 to 2011
$3.8M
Photodynamic Therapy (PDT) Mechanisms: Tumor ImmunityR01CA098156 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOLLNICK, SANDRA O. · 2003 to 2013
$3.6M
IRON, NO, AND LIPID PEROXIDES IN PHOTODYNAMIC THERAPYR01CA070823 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI GIROTTI, ALBERT · 1997 to 2015
$3.5M
Subcellular targets and PDT-induces cell deathR01CA023378 · NCI · WAYNE STATE UNIVERSITY · PI KESSEL, DAVID HARRY · 1985 to 2013
$3.3M
LIPID HYDROPEROXIDE CYTOTOXICITY AND DETOXIFICATIONR01CA072630 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI GIROTTI, ALBERT · 1998 to 2007
$1.8M
ROLE OF OXIDIZED CARDIOLIPIN TRANSLOCATION IN OXIDATIVE STRESS-INDUCED APOPTOSISR01HL085677 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI GIROTTI, ALBERT · 2007 to 2010
$1.3M
Optical Dosimetry for Clinical Trials of Pc 4 Photodynamic TherapyR01CA122093 · NCI · UNIVERSITY OF ROCHESTER · PI FOSTER, THOMAS HARRISON · 2006 to 2010
$1.2M
Macrophage Targeted Photodynamic TherapyR01CA083882 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2002 to 2004
$740k
NCI NIH HHS L30 CA136212NCI NIH HHS P01 CA055791NCI NIH HHS P01 CA087971NCI NIH HHS R01 CA023378NCI NIH HHS R01 CA068409NCI NIH HHS R01 CA070823NCI NIH HHS R01 CA072630NCI NIH HHS R01 CA083882NCI NIH HHS R01 CA098156NCI NIH HHS R01 CA122093NHLBI NIH HHS R01 HL085677NIAID NIH HHS R01 AI050875
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.

Indexed as

PhotochemotherapyHumansNeoplasmsPhotosensitizing AgentsPhotosensitizing Agents

Identifiers

PMID21617154
PMCPMC3209659
OpenAlexW2151734986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.